Ankylosing spondylitis treatment market is projected to grow at a considerable CAGR of around 5% during the forecast period (2020-2026). The growing incidence and prevalence of ankylosing spondylitis due to a sedentary lifestyle along with the introduction of novel products are expected to drive market growth over the forecast period. The increasing per capita income, improving healthcare infrastructure, and growing investment in R&D of novel therapies are the other factors that are contributing towards the growth of the global market. The HealthWell Foundation, an independent non-profit organization had launched a new program to assist patients who have been diagnosed with ankylosing spondylitis. 

The presence of such awareness programs to make people aware related to the treatment of ankylosing spondylitis is further contributing to the growth of the ankylosing spondylitis treatment market. However, patent loss, the launch of biosimilars, and the dearth of trained rheumatologists with proper skill and knowledge to perform proper treatment act as major restraints for the growth of the market across the globe. 

Segmental Outlook  

The ankylosing spondylitis treatment market is segmented on the basis of the drug into Secukinumab, Adalimumab, Golimumab, Infliximab, Etanercept, Certolizumab Pegol, and Other. Among these, Secukinumab is anticipated to exhibit considerable growth in the market. In October 2019, Novartis International AG, a pharmaceutical company had received approval from the European Commission (EC) to use Cosentyx (Secukinumab) for the treatment of active ankylosing spondylitis. Humira is anticipated to hold major market share during the forecast period. The cost-efficiency of these drugs along with high efficiency are the two major factors contributing to the high share of this segment in the global market. 

Global Ankylosing Spondylitis Treatment Market Share by Drug, 2019 (%)

Regional Outlook 

The global ankylosing spondylitis treatment market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a major market share in the global market during the forecast period. Higher incidence and prevalence rate of ankylosing spondylitis, proper medical reimbursement policies, the presence of advanced healthcare infrastructure are the key factors that are making a contribution towards the high share of the market in the region. Awareness related to the treatment of ankylosing spondylitis along with the adoption of newer treatment options and availability of improved diagnostic tools in the region is further expected to drive the market growth in the region. However, poor healthcare infrastructure, affordability issues, and lack of awareness related to the proper treatment options are the key factors that may hamper the market growth in the Middle East & Africa and Latin America region. 

Global Ankylosing Spondylitis Treatment Market Growth, by Region 2020-2026

Asia-Pacific will augment with the significant growth rate in the ankylosing spondylitis market

Improving healthcare infrastructure, increasing per capita healthcare expenditure, rising patient pool suffering from ankylosing spondylitis disorder, and growing R&D funding for new therapies, are anticipated to be the key factors driving the growth of the market in the Asia-Pacific region. However, low awareness related to the treatment options among the people of the low-income economies of the region is anticipated to hinder the growth of the ankylosing spondylitis treatment market in the Asia-Pacific region.  

Market Players Outlook

The key players of ankylosing spondylitis treatment market include AbbVie, Inc., Allergen Inc., Eli Lilly and Co., Merck & Co. Inc., Sanofi SA, Pfizer Inc., Bayer AG, Amgen Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Bristol-Myers Squibb, Co., Endo Health Solutions, Inc., and so on. These players are actively adopting growth strategies such as merger & acquisition, partnership, collaboration, strategic agreement, new product launches, and patent extension in order to enhance their market share. For instance, in May 2019, Abbvie’s Pharmaceutical had announced the patent extension of Humira drug, till 2023 in the US after making the settlement with Boehringer Ingelheim International GmbH. Under the terms of the settlement, Boehringer Ingelheim International GmbH will pay royalties to AbbVie for licensing its Humira patents. This company intends to establish its monopoly in the US market.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global ankylosing spondylitis treatment market. Based on the availability of data, information related to the products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.